• Keymed Biosciences’ board on Aug. 19, 2026 backed a plan to issue RMB-denominated ordinary shares for listing on Shanghai’s Sci-Tech Board.
• The move remains at an early stage with no regulatory filings made.
• Execution depends on market conditions, shareholder approval at a general meeting, board sign-off on a final plan, regulatory clearances.
• Investors were warned the Shanghai listing plan could change or be dropped.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12291024), on August 19, 2026, and is solely responsible for the information contained therein.